On Friday, Johnson & Johnson JNJ introduced discontinuing the Part 2 discipline examine evaluating the efficacy of investigational antiviral candidate mosnodenvir to forestall dengue virus in adults aged 18-65.
The decision to discontinue this examine is a part of a strategic reprioritization of the corporate’s Communicable Illnesses analysis and improvement (R&D) portfolio. No issues of safety had been recognized.
Efficacy information from the Part 2 discipline examine shall be obtainable as soon as the ultimate information analyses, which at the moment are underway, are full.
Additionally Learn: Johnson & Johnson’s Erleada Reveals Improved Total Survival In Prostate Most cancers Sufferers In contrast To Pfizer’s Drug.
Mosnodenvir (previously JNJ-1802) was proven to be protected and properly tolerated in earlier Part 1 and Part 2a scientific research.
In October 2023, outcomes from the Part 2a human problem examine discovered that the compound induced antiviral exercise in opposition to dengue (DENV-3) in people, in comparison with placebo.
The examine evaluated totally different dosing regimens – low, medium or excessive – of JNJ-1802 in opposition to an attenuated dengue 3 serotype (DENV-3) in wholesome adults.
All contributors acquired day by day doses of JNJ-1802 or a placebo over 26 days, throughout which they had been challenged with DENV-3 on day 5.
All contributors had been monitored over 85 days. The examine discovered a dose-dependent antiviral impact on the detectability of DENV-3 RNA and time to first onset of detectable DENV-3 RNA in comparison with placebo and was protected and well-tolerated.
In Could, Takeda Pharmaceutical Co Ltd’s TAK dengue vaccine acquired World Well being Group’s (WHO) prequalification.
TAK-003 is the second dengue vaccine to be prequalified by WHO.
WHO really helpful utilizing TAK-003 in youngsters aged 6–16 in settings with excessive dengue burden and transmission depth.
Worth Motion: JNJ inventory is down 0.60% at $159.53 on the final verify on Friday.
Learn Subsequent:
Picture by way of Shutterstock
Market Information and Knowledge dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
